Autolus Therapeutics in Partic – GuruFocus.com

LONDON, May 27, 2022 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies, today announces that management will attend the Jefferies Healthcare Conference at Marriott Marquis in New York City. Autolus Chief Executive Dr. Christian Itin will participate in a fireside chat on Thursday, June 9 from 9:00 a.m. to 9:30 a.m. ET (2:00 p.m. to 2:30 p.m. BST) and the company will also participate in individual meetings with investors. at the event.

An audio webcast of the Fireside Chat will be available in the Events section of the Autolus website. An archived version will also be available on the company’s website for a limited time after the call.

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. Using a wide range of proprietary and modular T cell programming technologies, the company designs targeted, controlled and highly active T cell therapies designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, visit www.autolus.com.

Contact:

Olivia Manser
+44 (0) 7780 471568
[email protected]

Julia Wilson
+44 (0) 7818 430877
[email protected]

Susan A. Noonan
SA Noonan Communications
+1-917-513-5303
[email protected]

Autolus-Inc-.png

Comments are closed.